Quarterly ResultAug 11, 2026, 07:01 AM
Gain Therapeutics Rexaceract IND Authorized for Phase 2; Q2 Net Loss $0.11/Share
AI Summary
Gain Therapeutics reported its Q2 2026 financial results and provided a corporate update, highlighted by the FDA's authorization of its IND for rexaceract, allowing advancement into Phase 2 clinical development. The company also shared positive Phase 1b data for rexaceract, demonstrating durable responses and perceived patient benefits. Financially, Gain Therapeutics reported a net loss of $0.11 per share for Q2 2026, an improvement from the prior year, with cash and equivalents at $13.1 million.
Key Highlights
- FDA authorized IND for rexaceract, enabling Phase 2 clinical development in Q3 2026.
- Rexaceract Phase 1b showed stable MDS-UPDRS scores and perceived patient benefits through Day 360.
- Q2 2026 net loss was $0.11 per share, compared to $0.19 per share in Q2 2025.
- Research and development expenses decreased by $0.6 million to $2.1 million in Q2 2026.
- General and administrative expenses increased by $0.2 million to $2.5 million in Q2 2026.
- Cash and cash equivalents were $13.1 million as of June 30, 2026.
- Dr. Joanne Taylor promoted to Chief Scientific Officer; Terenzio Ignoni to Chief Operating Officer.
- GT-04686 initial therapeutic indication expected by year-end 2026.
Price Impact
More from GANX